Dako, founded in 1966 in Denmark, was a global leader in cancer diagnostics, providing antibodies, reagents, instruments, and software to pathology laboratories. Renowned for its high-quality products and innovation in tissue-based cancer diagnosis, Dako played a significant role in advancing anatomical pathology. In 2012, Agilent Technologies acquired Dako for $2.2 billion, integrating its expertise and product lines into Agilent's life sciences and diagnostics portfolio to strengthen its position in the diagnostics market. Dako's legacy continues within Agilent's pathology solutions.
Served as the global headquarters, overseeing research and development, manufacturing, and global operations for Dako's diagnostic solutions prior to its acquisition by Agilent.
The Glostrup campus was a significant site for Dako's research, development, and production of antibodies and diagnostic instruments, featuring advanced laboratory and manufacturing facilities.
As a scientifically-driven company, Dako's culture emphasized innovation, quality, and collaboration, with a strong focus on contributing to cancer diagnostics and improving patient care.
The Glostrup headquarters was central to Dako's global impact on pathology and cancer diagnostics, being the hub of its innovation, product development, and manufacturing operations.
Prior to its 2012 acquisition by Agilent, Dako had a significant global footprint, with its products and services available in over 100 countries. This extensive reach was achieved through a combination of direct sales offices in key markets (e.g., North America, Europe, Japan), regional headquarters, and a broad network of distributors. Dako globally supported functions such as sales, marketing, customer service, technical support, and distribution for its comprehensive portfolio of anatomical pathology solutions, including antibodies, reagents, visualization systems, and automated instruments.
Produktionsvej 42
Glostrup
Capital Region
Denmark
Address: 6392 Via Real, Carpinteria, CA 93013, USA
Key center for supporting the Americas market, product development, manufacturing, and customer support for Dako's pathology solutions.
Address: Denmark House, Angel Drove, Ely, Cambridgeshire, CB7 4ET, UK
Primary base for serving the UK and Irish markets, providing localized commercial and technical support for Dako's portfolio.
Address: Nissei Fudosan Nishishinjuku Bldg. 8F, 5-8-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan (example historical address)
Facilitated Dako's business activities and customer relations in Japan, a key market for advanced diagnostic technologies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Dako' leadership includes:
Dako has been backed by several prominent investors over the years, including:
Dako was acquired by Agilent Technologies in 2012 and no longer operates as an independent entity. Therefore, executive news specifically for 'Dako' in the last 12 months is not applicable. Leadership changes related to former Dako product lines would occur within Agilent's Diagnostics and Genomics Group or relevant divisions.
Discover the tools Dako uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, before its acquisition by Agilent, Dako likely used common corporate email formats. These typically involved combinations of employee names and the company domain 'dako.com'. Post-acquisition, communication related to Dako products and services use Agilent's email system.
[first_initial][last_name]@dako.com (e.g., jsmith@dako.com) or [first_name].[last_name]@dako.com (e.g., jane.smith@dako.com) were plausible formats.
Format
lholmkvist@dako.com (hypothetical example based on common format)
Example
70%
Success rate
Agilent Technologies Newsroom • May 17, 2012
Agilent Technologies Inc. announced it had signed a definitive agreement to acquire Dako, a leading global provider of cancer diagnostics based in Denmark, for $2.2 billion. The acquisition aimed to significantly expand Agilent's presence in the diagnostics market....more
Dako Press Release / PR Newswire (Historical) • September 26, 2011
Dako announced FDA approval for its HER2 CISH pharmDx™ Kit, designed for the detection of HER2 gene amplification in breast cancer tissue. This approval marked another step in Dako's contribution to personalized medicine in cancer treatment....more
EQT Press Release (Historical) • June 1, 2007
The private equity fund EQT IV announced the acquisition of Dako A/S, a global leader in cancer diagnostics. The acquisition aimed to support Dako's continued growth and development in the anatomical pathology market....more
Company Archives / Historical Records • 1966
Dako was founded in 1966 in Copenhagen, Denmark, by Dr. Niels Harboe. Initially named Dakopatts A/S, the company focused on producing high-quality antisera for research and diagnostics, laying the foundation for its future as a global leader in immunochemistry and cancer diagnostics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Dako, are just a search away.